Insmed reported $151.62M in Operating Expenses for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Acelrx Pharmaceuticals ACRX:US $ 10.46M 805K
Alexion Pharmaceuticals ALXN:US $ 1000.3M 30.6M
Alimera Sciences ALIM:US $ 12.91M 736K
Arena Pharmaceuticals ARNA:US $ 144.39M 12.4M
Biomarin Pharmaceutical BMRN:US $ 461.96M 28.06M
Cytokinetics CYTK:US $ 57.64M 10.48M
Dynavax Technologies DVAX:US $ 48.83M 5.98M
Flexion Therapeutics FLXN:US $ 45.06M 2.67M
Gilead Sciences GILD:US $ 3971M 438M
Heron Therapeutics HRTX:US $ 82.91M 10.78M
Insmed INSM:US $ 151.62M 27.57M
Mirati Therapeutics MRTX:US $ 164.19M 31.76M
Novartis NVS:US 10.13B 319M
Regeneron Pharmaceuticals REGN:US $ 1791.3M 375.3M
Sarepta Therapeutics SRPT:US $ 331.66M 32.87M
Seattle Genetics SGEN:US $ 478.08M 23.68M
Ultragenyx Pharmaceutical RARE:US $ 169.75M 36.21M
Vertex Pharmaceuticals VRTX:US $ 1831.33M 994.85M